AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00395460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Description: 1,0M, intra venous injection at a dose of 0,1 ml/kg BW (= 0,1 mmol Gd/kg BW)
Study NCT00395460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnevist
Description: 0,5M, intra venous injection at a dose of 0,2 ml/kg BW (= 0,1 mmol Gd/kg BW)
Study NCT01006928 — intervention group
Intervention type: OTHER
Intervention: Questionaire
Description: Questionaire to mothers
Study NCT03604523 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dilation by Balloon
Description: Esophageal dilation by balloon device.
Study NCT03604523 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dilation by Semi-rigid Savary
Description: Esophageal dilation by semi-rigid savary device
Study NCT01136772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: haloperidol decanoate
Description: haloperidol decanoate injections, 25-200 mg once a month
Study NCT01136772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paliperidone palmitate
Description: Paliperidone palmitate injections, 39 mg - 234 mg once a month
Study NCT01100034 — intervention group
Intervention type: DRUG
Intervention: Etanercept
Description: Expected duration of 24 weeks as one course
Study NCT02931825 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder letter
Description: The letter will consist in several parts:~* Reminder of : -the need of individual follow-up for high risk people for colorectal cancer AND - the general recommendations (one colonoscopy every 5 years)~* Recommendation to consult their general practitioner or gastroenterologist if they haven't done their follow up~* Request information if they've done their follow-up or if we have incorrect information~* Indication that the letter is sent as part of a surveillance program specific for high risk people for colorectal Cancer
Study NCT04572087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral training and verum stimulation
Description: Cognitive control training and verum tDCS
Study NCT04572087 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral training and sham stimulation
Description: Cognitive control training and sham tDCS
Study NCT03760705 — intervention group
Intervention type: OTHER
Intervention: Data Collection
Description: 1. Collection of data as detailed below:~   1. Clinical data collected by SCDB~  2. Clinical, administrative, pharmacy, financial data collected by each participating hospital~  3. Administrative data collected by MOH~2. Data will be extracted and anonymized on a secure healthcare analytics platform~3. Collaboration with the MOH for collection of administrative and financial data~4. Analysis on how healthcare behavior is affected by education, socioeconomic level and other social or cultural factors.~5. Statistical Analysis by the bio statistical team. This team will be responsible for collecting and merging the collected data and will also ensure the quality of the data.
Study NCT04631419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flapless laser corticotomy
Description: The flapless laser corticotomy will be done by Er, Cr: YSGG laser as a series of circular holes will be made along with the planned position. The depth of laser cutting will be measured and controlled continuously during the operation by the periodontal probe with stopper read to each 3mm depth in addition to a few parts of a millimetre depth into the medullary bone to enhance bleeding. Canine retraction will be started after this procedure.
Study NCT04631419 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Canine retraction
Description: canine retraction will be done on 17x25 stst archwire using coil spring adjusted to 150 gm, and miniscrews will be used as an indirect method of anchorage reinforcement
Study NCT04631419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Canine retraction
Description: canine retraction will be done on 17x25 stst archwire using coil spring adjusted to 150 gm, and miniscrews will be used as an indirect method of anchorage reinforcement
Study NCT00452088 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSP 3 Long Synthetic Peptide
Description: Lyophilized vaccine given at 15 or 30 microgrammes
Study NCT00452088 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B vaccine
Description: Hepatitis vaccine adjuvanted in Aluminium hydroxide
Study NCT00452088 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B control vaccince
Description: Hepatitis B vaccine adjuvanted in Aluminium hydroxide
Study NCT03134157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral drug and vaginal placebo
Description: prescription of simvastatin 40 mg orally+ vaginal placebo every day for 3 months.
Study NCT03134157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral drug and oral placebo
Description: prescription of simvastatin 40 mg orally+ oral placebo every day for 3 months.
Study NCT03134157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal placebo+ oral placebo
Description: prescription of Vaginal placebo + oral placebo every day for 3 months.
Study NCT02354443 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ProHema-CB Transplant
Description: ProHema-CB, the cellular product, represents the cell populations contained within a human UCB unit after modulation on the day of transplantation by an ex vivo incubation process with the prostaglandin derivative, 16,16-dimethyl prostaglandin E2 (also referred to as FT1050). The cell populations include hematopoietic stem and progenitor cells.
Study NCT00141726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept will be given on an open label, single arm basis to patients with non-infectious, sub-acute lung injury. 0.4 mg/kg/dose to a maximum of 25 mg, subcutaneously, twice weekly, for a total of 24 dosages.
Study NCT02681133 — intervention group
Intervention type: OTHER
Intervention: Epidemiological study Survey
Study NCT00829582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETI-204, Anthim
Description: single intravenous infusion of 120, 240 or 360 mg of ETI-204
Study NCT00829582 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: placebo
Description: single intravenous infusion
Study NCT02038439 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention A - Online Clinical Questions Recorder
Description: Clinicians allocated to this intervention will receive access to an online recorder for the clinical questions at the point of care. The recorder is accessible across a wide range of devices including phones, tablets, and desktop computers.
Study NCT02038439 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention B - Online Evidence Retrieval Coach
Description: Clinicians allocated to this intervention will receive online guidance, embedded in the MPFS search engine, in the form of short videos, animations, demos and tips and tricks regarding evidence retrieval.
Study NCT02038439 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention C - Online Audit and Feedback
Description: Clinicians allocated to this intervention will receive feedback on their current search performance compared to their peers, both online when using MPFS as well as by e-mail.
Study NCT03046784 — intervention group
Intervention type: OTHER
Intervention: haemodynamic evaluation
Description: continous haemodynamic monitoring is performed with digital Nexfin captor in two positions. in the same time transthoracic cardiac ultrasonography is performed to calculate cardiac output using velocity time index of aortic outflow chamber.
Study NCT01164124 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (Lactobacillus rhamnosus GG and Bifidobacterium infantis)
Description: The probiotic regimen consisted of 500 million CFU of Lactobacillus rhamnosus GG (Culturelle, Amerifit Brand Inc.) and 500 million CFU of Bifidobacterium infantis (Align, Procter \& Gamble.Inc)
Study NCT01164124 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: routine feedings
Study NCT04015856 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full TP intervention
Description: CARE's Tipping Point initiative focuses on addressing the root causes of child, early, and forced marriage (CEFM) and promoting the rights of adolescent girls through community-level programming and evidence generation in Nepal and Bangladesh, as well as multi-level advocacy and cross-learning efforts across the globe. Tipping Point's approach focuses on synchronized engagement with different participant groups-including adolescent girls, adolescent boys, parents/community members, community leaders-around key programmatic pillars, and creates public spaces for all community members to engage in the dialogue. Tipping Point's approach relies on challenging social expectations and repressive gender norms and promoting girl-centric and girl-led activism to enable adolescent girls to identify and move into social spaces where they can challenge inequality.
Study NCT04015856 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Light TP intervention
Description: The Tipping Point project also has designed a social norms light package, which includes a subset of the social norms and activism components of the full package.
Study NCT03281837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HYMOVIS plus Physical Exercise Program (PEP)
Description: 1 injection of intra-articular (IA) hyaluronan (HA), Hymovis 24mg/3ml, injection per week for 2 weeks combined with at least 8 weeks of Physical Exercise Program (PEP)
Study NCT03281837 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: HYMOVIS plus Physical Exercise Program (PEP)
Description: 1 injection of intra-articular (IA) hyaluronan (HA), Hymovis 24mg/3ml, injection per week for 2 weeks combined with at least 8 weeks of Physical Exercise Program (PEP)
Study NCT03281837 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical Exercise Program (PEP) alone
Description: Physical Exercise Program (PEP) alone for at least 8 weeks
Study NCT03741933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 30mg
Description: Apremilast 30 mg tablet
Study NCT03758287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT053PTSA
Study NCT03758287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Study NCT01434615 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT
Description: Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) and receive CRT-P or CRT-D device
Study NCT01434615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No-CRT
Description: Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) but who do not get a CRT-P or CRT-D device implanted
Study NCT04441892 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QTc Meter
Description: Development and evaluation of an inexpensive diagnostic device (the QTc Meter) to support simplified widespread screening in the primary care environment for both congenital long QT syndrome (LQTS) and acquired/drug induced-LQTS.
Study NCT02545985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prolim stent deployment
Description: Prolim stent was implanted in patients who signed the informed consent and met the exclusion and inclusion criteria.
Study NCT01849991 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri
Description: Lactobacillus reuteri oil drops are a natural product containing Lactobacillus reuteri (LR), which has traditionally been used for the establishment of a well-functioning gastrointestinal (GI) microbiota and prevention and treatment of mild diarrhea associated with GI-tract infections, travel or antibiotic treatment.~The drug is a clear liquid when suspended in sunflower oil. The drug will be administered orally, 0.2cc once daily.
Study NCT01849991 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is sunflower oil (vehicle for LR). The placebo will be administered the same way as drug listed above.
Study NCT04286945 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: LATERAL RECTUS MUSCLE AUGMENTED RECESSION BY ELONGATION OF THE TENDON WITH AUTOGRAFT FROM RESECTED MEDIAL RECTUS MUSCLE
Description: After resection of the medial rectus muscle, the resected segment is sutured to the lateral rectus muscle after dissection and marking to elongate and slaken the muscle then the elongated muscle is sutured to the sclera at the desired amount of conventional recession.
Study NCT02546271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GPS
Study NCT00267059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 10 mg/day, orally once a day for 28 days
Study NCT01173367 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aggressive Fever Treatment
Description: Patients assigned to the aggressive fever treatment protocol will receive acetaminophen 650 mg enterally every 6 hours for fever ≥ 38.3°C and external cooling will be initiated for temperatures ≥ 39.5°C. Acetaminophen and external cooling will be discontinued once core temperature is less than 38.3°C and 39.5°C respectively.
Study NCT01173367 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Permissive Fever Treatment
Description: Patients assigned to the permissive treatment strategy will not receive anti-pyretic therapy until the temperature reaches 40.0°C at which point they will receive acetaminophen 650mg every 6 hours. External cooling will be initiated for temperatures ≥ 40.5°C. Acetaminophen and external cooling will be discontinued once core temperature is less than 40.0°C and 40.5°C respectively.
Study NCT01232023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indobufen
Description: Single Oral Dose of
Study NCT03839160 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus anterior plane block
Description: Serratus anterior plane block was applied in Group S. It was performed at the end of the operation following the skin closure, while the patient lay on his side with his arm above the head. After proper site cleaning, the first and second ribs were identified with a linear probe in the midclavicular line. The USG probe was advanced caudally in the sagittal plane, and the fourth and fifth ribs were visualized. The USG probe was then directed posteriorly and the serratus, latissimus dorsi and intercostal muscles were visualized. Bupivacaine 0.25% 30 mL was administered to the lower plane of the serratus muscle through an inserted catheter under the guidance of USG through the in-line technique. Afterwards, 0.12% bupivacaine hydrochloride was maintained at the rate of 0.1ml/kg/hr.
Study NCT03839160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous patient-controlled-analgesia morphine
Description: Morphine solution was prepared at a concentration of 0.5 mg/mL with the device programmed to 2 mg of bolus dose and 10 min of locking time.
Study NCT03839160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous patient-controlled-analgesia morphine
Description: Morphine solution was prepared at a concentration of 0.5 mg/mL with the device programmed to 2 mg of bolus dose and 10 min of locking time.
Study NCT00549835 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Real Acupuncture
Study NCT00549835 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Real Acupuncture
Study NCT00549835 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Acupuncture
Description: Sham needles are developed to exclude sham effect and to prove real acupuncture efficacy. We will use specifically retractable Park Sham Device (AcuPrime, Exeter, UK) for control group. Because this sham device gives the impression of insertion with telescopic needle body and some pricking sensation with a bunt needle tip. It is a valid control for many acupuncture trials as it doesn't penetrate skin and doesn't create active stimulation as much as real needles or acupressure. To avoid unnecessary stimulation of penetrating skin in this population, we plan to use non-penetrating sham device rather than penetrating non-acupuncture point with real needles as control intervention.~All other procedures will be same as Real Acupuncture group except using non-penetrating sham needles on non-acupuncture points. After final session, we will ask all subjects in both groups which form of treatment each subject believe to have during study and will analyze blinding credibility.
Study NCT00549835 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Sham needles are developed to exclude sham effect and to prove real acupuncture efficacy. We will use specifically retractable Park Sham Device (AcuPrime, Exeter, UK) for control group. Because this sham device gives the impression of insertion with telescopic needle body and some pricking sensation with a bunt needle tip. It is a valid control for many acupuncture trials as it doesn't penetrate skin and doesn't create active stimulation as much as real needles or acupressure. To avoid unnecessary stimulation of penetrating skin in this population, we plan to use non-penetrating sham device rather than penetrating non-acupuncture point with real needles as control intervention.~All other procedures will be same as Real Acupuncture group except using non-penetrating sham needles on non-acupuncture points. After final session, we will ask all subjects in both groups which form of treatment each subject believe to have during study and will analyze blinding credibility.
Study NCT00936767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemisone/Mefloquine (AmiM3)
Description: Artemisone 4 mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
Study NCT00936767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate
Description: Artesunate 4mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
Study NCT01501565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative transverse abdominal plain (TAP) blockade
Description: Bupivacaine 0.25%. Maximum 150 mg. A maximum of 75 mg bupivacaine is administered in each side (posterior and subcostal TAP) in a single puncture.
Study NCT01735006 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV Vaccine
Description: 3 doses at month 0,1 and 6
Study NCT01735006 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: HEV vaccine
Description: 3 doses at month 0,1 and 6
Study NCT02960581 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGT121 3mg/kg IV
Description: 3mg/kg administered by IV Infusion
Study NCT02960581 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGT121 10mg/kg IV
Description: 10mg/kg administered by IV infusion
Study NCT02960581 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGT121 30mg/kg IV
Description: 30mg/kg administered by IV infusion
Study NCT02960581 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGT121 3mg/kg SC
Description: 3mg/kg administered by SC injection~Placebo: None
Study NCT02960581 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (0.9% Sodium Chloride Injection USP (Saline))
Study NCT03762057 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Intraabdominal pressure monitoring
Description: Classic manometry technique measurement once daily
Study NCT04363970 — intervention group
Intervention type: OTHER
Intervention: removal of the urinary catheter
Description: in group A, we will remove the catheter after 24 h. In group B, we will remove the catheter after 48 h.
Study NCT02341183 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tPAD
Description: 7% NaCl administered continuously for 8 hours, overnight, via the tPAD device
Study NCT02341183 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 7% hypertonic saline (510K approved as a device)
Description: Subjects will receive overnight treatments of 7% HS via the tPAD device in both comparators, but in a randomly assigned order as described.
Study NCT00674817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 microgrammes GSK961081
Description: Inhaled GSK961081 administered via Dry Powder Inhaler.
Study NCT00674817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 400 microgrammes GSK961081
Description: Inhaled GSK961081 administered via Dry Powder Inhaler.
Study NCT00674817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1200 microgrammes GSK961081
Description: Inhaled GSK961081 adminisntered via dry powder inhaler.
Study NCT00674817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1200 microgrammes GSK961081
Description: Inhaled GSK961081 adminisntered via dry powder inhaler.
Study NCT01958372 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy isoflavones
Description: Given PO
Study NCT01958372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT01958372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT01958372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Given IV
Study NCT01958372 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo RT
Study NCT01939613 — intervention group
Intervention type: DRUG
Intervention: colloids
Description: TMMU group allows for administration of colloids early,while Parkland group infuse colloids 24 h after burn injury.
Study NCT01582893 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HCO1100
Description: Dialysis